0001209191-18-025047.txt : 20180416 0001209191-18-025047.hdr.sgml : 20180416 20180416181525 ACCESSION NUMBER: 0001209191-18-025047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180412 FILED AS OF DATE: 20180416 DATE AS OF CHANGE: 20180416 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ANIDO VICENTE JR CENTRAL INDEX KEY: 0001207633 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36152 FILM NUMBER: 18757553 MAIL ADDRESS: STREET 1: 1621 BAYSIDE DR CITY: CORONA DEL MAR STATE: CA ZIP: 92625 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AERIE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001337553 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 203109565 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7020 KIT CREEK ROAD STREET 2: SUITE 270 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919-313-9650 MAIL ADDRESS: STREET 1: 7020 KIT CREEK ROAD STREET 2: SUITE 270 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-04-12 0 0001337553 AERIE PHARMACEUTICALS INC AERI 0001207633 ANIDO VICENTE JR C/O AERIE PHARMACEUTICALS, INC. 4301 EMPEROR BLVD., SUITE 400 DURHAM NC 27703 1 1 0 0 Chief Executive Officer Common Stock 2018-04-12 4 A 0 21448 0.00 A 133926 D Common Stock 2018-04-12 4 F 0 3149 53.40 D 130777 D The reported transaction includes (i) 10,724 shares of common stock that vested on April 12, 2018 and (ii) 10,724 shares of common stock that will vest on April 12, 2019, subject to the reporting person's continued employment with the issuer through such date, pursuant to, in the case of each of clauses (i) and (ii), the issuer's compensation committee having determined that the requisite performance condition (the approval and launch of Rhopressa prior to September 30, 2018) has been achieved. /s/ Richard J. Rubino, Attorney-in-Fact for Vicente Anido, Jr. 2018-04-16